References
- Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474–9
- American Heart Association. Heart disease and stroke statistics – 2005 update. Dallas (TX): American Heart Association; 2005
- Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl 1995;168:7–12
- Man in’t Veld AJ. Symptomatic BPH and hypertension: does comorbidity affect quality of life? Eur Urol 1998;34(Suppl 2):29–36
- Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005;173:1256–61
- Barry MJ, Fowler Jr FJ, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia [The Measurement Committee of the American Urological Association]. J Urol 1992;148:1549–57
- Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993;150:85–9
- Sarma AV, Jacobson DJ, McGree ME et al. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol 2005;173:2048–53
- Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 2005;173:1309–13
- Michel MC, Heemann U, Schumacher H, et al. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004;172:1390–3
- Weisman KM, Larijani GE, Goldstein MR, et al. Relationship between benign prostatic hyperplasia and history of coronary artery disease in elderly men. Pharmacotherapy 2000;20:383–6
- Dang DK, Pont JM, Portnoy MA. Episode treatment groups: an illness classification and episode building system – part I. Med Interface 1996;9:118–22
- Dang DK, Pont JM, Portnoy MA. Episode treatment groups: an illness classification and episode building system – part II. Med Interface 1996;9:122–8
- Department of Labor, Bureau of Labor Statistics. Available at www.bls.gov [accessed January 2006]
- Sugaya K, Kadekawa K, Ikehara A, et al. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol 2003;10:569–74
- Pool JL. Role of the sympathetic nervous system in hypertension and benign prostatic hyperplasia. Br J Clin Pract Suppl 1994;74:13–7
- de Mey C. Cardiovascular effects of alpha-blockers for the treatment of symptomatic BPH. Eur Urol 1998;34(Suppl 2):18–28
- ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Am Med Assoc 2000;283:1967–75
- AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003); chapter 1: diagnosis and treatment recommendations. J Urol 2003;170: 530–47
- Trueman P, Hood SC, Nayak USL, et al. Prevalence of lower urinary tract symptoms and self-reported diagnosed ‘benign prostatic hyperplasia’ and their effects on quality of life in a community-based survey of men in the UK. Br J Urol Int 1999;83:410–5
- Lloyd-Jones DM, Evans JC, Larson MG, et al. Treatment and control of hypertension in the community: a prospective analysis. Hypertension 2002;40:640–6